Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Deborah Anzalone"'
Autor:
Gabriel I. Uwaifo, Deborah Anzalone, Fan Mu, Erin E. Cook, Vivian Fonseca, Lei Yin, Jill Davis, Harold M. Szerlip, Rubeen Israni, Keith A. Betts, Eric Q. Wu
Publikováno v:
Advances in Therapy
Introduction Although hyperkalemia and metabolic acidosis often co-occur in patients with chronic kidney disease (CKD), the prevalence of metabolic acidosis among patients with CKD and hyperkalemia is understudied. Therefore, we used medical record d
Autor:
Temitope Olufade, Siting Zhou, Deborah Anzalone, David M. Kern, Ozgur Tunceli, Mark J. Cziraky, Vincent J. Willey
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 5 (2017)
BackgroundThe purpose of this study was to characterize changes in statin utilization patterns in patients newly initiated on therapy in the 2 years following the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA)
Externí odkaz:
https://doaj.org/article/3311b98290d74157aeabd355622f2957
Autor:
Deborah Anzalone, Jessie Wang, Fan Mu, Jill Davis, Vivian Fonseca, Keith A. Betts, Eric Q. Wu, Rubeen Israni, Harold M. Szerlip, Gabriel I. Uwaifo
Publikováno v:
Advances in Therapy
Introduction The progression of mild hyperkalemia and the predictors of progression have not been well characterized. In this study we aimed to characterize the progression of hyperkalemia and identify the risk factors for hyperkalemia progression. M
Autor:
Gregory A. Nichols, Maureen O’Keeffe-Rosetti, Teresa M. Kimes, Deborah Anzalone, Temitope Olufade, Daniel S. Sapp, Kristi Reynolds, Stephen P. Fortmann
Publikováno v:
The American Journal of Cardiology. 119:410-415
High triglyceride (TG) levels among patients with type 2 diabetes mellitus (DM) are associated with higher medical costs. We analyzed the economic impact of TG-lowering therapies and whether the association between medical costs and therapy differed
Autor:
Donald G. Vidt, Giuseppe Remuzzi, Hans-Henrik Parving, Deborah Anzalone, Dick de Zeeuw, John T. Monyak, Michael D. Cressman, Bruce A. Molitoris, Hiddo J.L. Heerspink, James R. Sowers, Valerie A. Cain
Publikováno v:
Lancet Diabetes & Endocrinology, 3(3), 181-190. ELSEVIER SCIENCE INC
Summary Background The role of lipid-lowering treatments in renoprotection for patients with diabetes is debated. We studied the renal effects of two statins in patients with diabetes who had proteinuria. Methods PLANET I was a randomised, double-bli
Autor:
Temitope Olufade, Deborah Anzalone, Elisabetta Malangone-Monaco, Stephen S. Johnston, Kristin A Evans, Sandra J. Lewis
Publikováno v:
Current medical research and opinion. 34(10)
Initial statin therapy may not always adequately reduce elevated low-density lipoprotein cholesterol (LDL-C) levels. Although alternative therapies are available, switching to another statin may be beneficial, especially for those at highest risk of
Publikováno v:
Current Medical Research and Opinion. 30:2443-2451
To compare clinical characteristics, statin treatment patterns and adherence among patients at different risk for coronary heart disease (CHD) as defined by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.Pati
Autor:
Gregory A Nichols, Kristi Reynolds, Teresa M Kimes, Tope Olufade, Deborah Anzalone, Stephen P Fortmann
Publikováno v:
Circulation. 133
Background: Severe hypertriglyceridemia is an often-neglected risk factor that is associated with increased risk of cardiovascular disease, pancreatitis and mortality, especially when other comorbidities are present. We investigated the association b
Autor:
Tope Olufade, Deborah Anzalone, David M Kern, Ozgur Tunceli, Siting Zhou, Vince Willey, Mark J Cziraky
Publikováno v:
Circulation. 132
Introduction: To characterize changes in statin utilization patterns after the release of the 2013 ACC/AHA cholesterol management guideline. Methods: Using administrative claims and laboratory results data from the HealthCore Integrated Research Data
Publikováno v:
Current Medical Research and Opinion. 22:2575-2590
The Glucose and Lipid Assessment in Diabetes (GLAD) trial examined the dose-response relationship of the dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar in type 2 diabetic patients.GLAD was a 12-week, multicent